New paradigm for treating 'inflammaging' and cancer

(Buck Institute for Age Research) Intermittent dosing with rapamycin breaks the inflammatory loop associated with senescence. Once disrupted, it takes time for the loop to reestablish itself -- providing proof-of-principal that intermittent dosing could provide a way to reap the benefits of rapamycin while bypassing its safety issues. The FDA-approved drug increases healthspan and lifespan in mice.DNA-damaging chemotherapies cause senescence in the tumor microenvironment. In mice, intermittent d...